Charlotte's Web Holdings, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Charlotte's Web Holdings, Inc. stands as a botanical wellness innovator, deeply involved in the cultivation, manufacturing, marketing, and distribution of hemp-derived cannabidiol (CBD) and an expanding portfolio of other plant-based wellness products. The company's diverse product categories include hemp extract oil tinctures, a variety of gummies crafted for sleep, calming, immune support, and exercise recovery, along with CBN gummies and their Brightside line of micro-dosed hemp-derived THC gummies tailored for specific effects like unwinding, focus, and restful sleep. Additionally, they offer CBD capsules, topical creams, lotions, and specialized CBD solutions for pets, complemented by new functional mushroom gummies targeting areas such as focus, stress relief, energy, and muscle recovery. These distinct offerings are presented under established brands including Charlotte's Web, CBD Medic, and CBD Clinic. Their premium extracts are recognized for their naturally occurring blend of phytocannabinoids, encompassing CBD, cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), and minor cannabinoids, alongside terpenes and flavonoids. Charlotte's Web distributes its products through a comprehensive omnichannel approach, leveraging its direct-to-consumer e-commerce platform, various third-party online marketplaces, a broad network of brick-and-mortar retailers including major grocery chains, health stores, and a channel catering to healthcare practitioners across the United States. As a Certified B Corporation, the company operates with a substantially vertically integrated model, ensuring stringent quality control from proprietary hemp genetics grown on family farms to the final product, validated by extensive in-house and third-party testing protocols. Recent strategic initiatives include the formation of a Scientific Advisory Board in September 2025, aimed at advancing medical research and development within the botanical wellness sector. Notably, through its collaboration, DeFloria, Inc., has secured FDA clearance to proceed with Phase 2 clinical trials for AJA001 Oral Solution, an investigational botanical drug for treating irritability associated with autism spectrum disorder, with Charlotte's Web holding exclusive manufacturing rights. The company has also prioritized operational efficiencies, including transitioning to in-house manufacturing for certain product lines, projecting significant annualized cost reductions and a trajectory towards positive cash flow by 2026. Charlotte's Web Holdings, Inc., originally established in 2013, is presently headquartered in Louisville, Colorado.
Charlotte's Web Appoints Jeff Raborn to Board of Directors
Charlotte's Web Announces Closing of Transaction with British American Tobacco, Including US$10 Million Investment
Charlotte's Web Reports Shareholder Meeting Voting Results
Charlotte's Web First Quarter 2026 Financial Results
CURED Nutrition Joins One Hemp, Strengthening Industry Alignment Ahead of Key Federal Legislative Deadline
Charlotte's Web Holdings, Inc. (CWEB:CA) Q4 2025 Earnings Call Transcript
Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results
Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance Sheet
Charlotte's Web 2025 Fourth Quarter and Year-End Earnings Call and Webcast Notice
Charlotte's Web Welcomes New CMS Guidance, Advancing Access to Eligible Full‑Spectrum Hemp Products
Charlotte’s Web (OTCMKTS:CWBHF) Stock Price Up 3.4% – Time to Buy?
Charlotte's Web Commends Representative Griffith for Leadership Introducing Hemp Enforcement, Modernization, and Protection (HEMP) Act
Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development
Charlotte's Web Serves as a Premier CBD Partner for Landmark Medicare and Medicaid Pilot Program
Charlotte's Web Reports Q3 2025 Results
Charlotte's Web Appoints M. Borgia Walker to Board of Directors
Charlotte's Web™ Expands its Brightside Line with Launch of Knockout Hemp THC Sleep Gummies
Charlotte's Web™ Expands Sleep Category with Launch of Quiet Sleep Mushroom Gummies
Charlotte's Web Announces Plans to Establish a Scientific Advisory Board
Charlotte's Web Holdings, Inc. (CWBHF) Q2 2025 Earnings Conference Call Transcript